GLP-3R

GLP-3R is a supplier designation, not a molecule with an entry in the chemical literature. It refers to a proprietary research construct positioned within the incretin and metabolic signaling space. The most useful thing this page can do is state clearly what is and is not known about it, because the honest answer is that very little is known about the construct itself, and considerably more is known about the receptor biology it is named after.

The first point of confusion to remove is the name. There is no receptor called GLP-3R in human physiology, no gene by that name in the human genome, and no such entry in the IUPHAR receptor nomenclature. The incretin and glucagon receptor family recognized in the literature consists of the glucagon-like peptide-1 receptor (GLP1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR), all class B1 secretin-family G protein-coupled receptors. The 3R in the product name appears to reference the concept of engaging three receptors, a design strategy that does exist in the peer-reviewed unimolecular polyagonist literature, rather than naming any receptor that exists.

Response BioLabs supplies this material for laboratory research use only. It is not an approved drug in any jurisdiction, it is not a clinical candidate with a published development program, and it is not equivalent to any commercial pharmaceutical product. Any researcher considering work with it should begin from the position that its identity and potency are unestablished until independently verified for the specific lot in hand.

The scientific background begins in 1964, when two independent groups reported that oral glucose produces a substantially larger insulin response than intravenous glucose does at matched blood glucose levels. That difference, later named the incretin effect, implied that the gut releases factors that potentiate insulin secretion. Glucose-dependent insulinotropic polypeptide was isolated and sequenced from intestinal extracts in 1971. Glucagon-like peptide-1 was identified in the 1980s from the cloned proglucagon gene, and subsequent work established that the biologically active species is the processed form GLP-1(7-36)amide rather than the full-length product.

Two findings in the following decade shaped everything that came after. In 1993 dipeptidyl peptidase-4 was identified as the enzyme responsible for rapid inactivation of both GLP-1 and GIP in serum, cleaving after the second residue and giving native GLP-1 a circulating half-life measured in minutes. That established protease resistance as the central design constraint for anything built on this pathway. In parallel, receptor cloning and characterization defined GLP1R, GIPR, and GCGR as distinct class B1 receptors with overlapping but non-identical tissue distributions and downstream consequences.

From roughly 2009 onward, academic and industrial groups reported unimolecular peptides engineered to engage two or three of these receptors at deliberately tuned potency ratios, with the underlying logic that combining incretin receptor engagement with glucagon receptor engagement might address glucose handling and energy expenditure through complementary rather than redundant routes. That published polyagonist literature is real, is peer reviewed, and is the conceptual origin of the naming convention used by research-market constructs like this one. What does not exist is any published characterization tying the GLP-3R designation to a specific sequence, receptor selectivity profile, or dataset.

The composition of this construct is proprietary and is not disclosed at the sequence level, which is why the chemistry fields on this page are left empty rather than filled with plausible-looking values. There is no published sequence, no assigned CAS number, no established molecular formula, and no reference molecular weight for GLP-3R as a designation. A supplier that presents such values without a supporting analytical basis is presenting an assumption as a specification.

This has direct methodological consequences. A blended or multi-component preparation cannot be meaningfully summarized by a single purity percentage, because that figure describes the fraction of material corresponding to one target species and says nothing about the ratio between species. For a construct in this category, the analytical package that carries real information is a mass spectrometry profile identifying each component present, a reversed-phase HPLC trace showing the relative abundance of each species, and a statement of net peptide content that accounts for water and counterion.

Peptides in this pathway family generally share certain physical characteristics that inform handling regardless of exact composition. They are typically longer than twenty residues, are supplied as lyophilized powders, are hygroscopic, and degrade in aqueous solution by backbone hydrolysis at a rate that increases sharply with temperature. Sequences in this family commonly carry engineered features intended to slow proteolysis, and adsorptive loss to glass and untreated plastic at low working concentrations is a known source of quantitative error. None of this is specific to GLP-3R, and none of it substitutes for lot-level characterization.

The receptors this construct is named after signal through well-mapped pathways. GLP-1R is a class B1 G protein-coupled receptor that couples primarily to Gs, activating adenylyl cyclase and raising intracellular cyclic AMP. In pancreatic beta cells this potentiates glucose-stimulated insulin secretion through protein kinase A and through Epac2, and the potentiation is glucose-dependent, meaning receptor engagement amplifies an existing secretory signal rather than generating one at low glucose. GLP1R is also expressed in regions of the central nervous system, in the gastrointestinal tract, and elsewhere.

GIPR is likewise Gs-coupled and is expressed on beta cells and on adipocytes, where its role in nutrient handling has been studied extensively and remains an area of genuine scientific disagreement, with both agonism and antagonism at this receptor investigated in the published literature for different reasons. GCGR is Gs-coupled on hepatocytes, where its canonical role is mobilization of hepatic glucose output, and where the polyagonist literature has examined its contribution to energy expenditure as a counterweight to incretin receptor engagement.

Beyond G protein coupling, these receptors recruit beta-arrestin and undergo internalization, and the balance between sustained cyclic AMP signaling and receptor desensitization is a well-documented determinant of how a given ligand behaves over time. This is described in the literature as signaling bias, and it is one reason two compounds with similar receptor affinities can produce different functional profiles.

It must be stated plainly that the preceding paragraphs describe receptor biology, not this product. Whether this specific construct engages any of these receptors, at what affinity, with what selectivity ratio, and with what signaling profile has not been published or independently determined. Assuming pathway engagement from a product name is not a scientific inference.

What is established: incretin receptor pharmacology is a mature field. The identity, structure, and coupling of GLP1R, GIPR, and GCGR are known, including cryo-electron microscopy structures of receptor complexes. The glucose-dependence of GLP-1R-mediated insulin potentiation, the role of dipeptidyl peptidase-4 in ligand inactivation, and the physiology of the incretin effect are all supported by decades of independently replicated work in multiple species including humans.

What is established about the unimolecular polyagonist concept: published academic work has reported that single peptides engineered to engage multiple receptors in this family produce metabolic effects in rodent models that differ from single-receptor engagement, and several such molecules have progressed into formal clinical development programs with published results. Those results belong to specific, fully characterized molecules with disclosed sequences and registered trial data. They do not belong to unrelated material that shares a conceptual category.

What is preliminary regarding GLP-3R specifically: there are no peer-reviewed publications on this construct. No receptor binding assay, no functional cyclic AMP assay, no selectivity profile, no animal pharmacokinetics, no animal efficacy study, and no human data of any kind exist for it in the published literature. Its stability profile, its degradation products, and its behavior in common assay buffers are undocumented. This is the weakest evidence position of any compound in this library, and the tier assigned here reflects that.

The practical guidance that follows is straightforward. A construct with no published characterization is a subject for characterization, not a tool to be used as though its properties are known. Researchers working with it should plan to establish identity and potency themselves, should treat lot-to-lot variability as a live experimental variable rather than an assumption, and should not import conclusions from the published literature on characterized molecules in this receptor space.

Lyophilized material is stored at -20 C or below for long-term inventory, with 2 to 8 C acceptable for short-term working stock. The powder is hygroscopic, so vials should be equilibrated to room temperature before opening to prevent condensation onto cold material, then resealed promptly. Protection from light is standard practice for peptide inventory.

For reconstitution, diluent is added slowly against the vial wall rather than directly onto the powder cake, and the vial is swirled gently or allowed to dissolve undisturbed. Vortexing and shaking generate shear and foaming at the air-liquid interface, which promotes aggregation and adsorptive loss. If material does not fully dissolve, the correct response is to document the observation and consult the lot certificate, not to increase agitation.

Reconstituted solutions are held at 2 to 8 C, protected from light, and aliquoted into single-use volumes so that repeated freeze and thaw cycles do not silently erode concentration between experiments. Because this construct has no published stability data, researchers should treat solution stability as unknown and should verify concentration analytically rather than relying on the nominal figure, particularly for any experiment where potency is the measured variable. Label aliquots with the lot number as well as the compound name, since lot identity is the only meaningful traceability handle for a material with no reference standard.

The question researchers ask most often is what the name actually denotes. The answer is that it is a market designation. GLP-3R does not appear in receptor nomenclature databases, in the human genome, or in the peer-reviewed literature as a molecular entity. It is best read as indicating a construct positioned in the incretin and metabolic signaling space, with the numeral referencing the multi-receptor design concept rather than a receptor subtype.

The second question is what documentation to require. For any uncharacterized or blended construct, the minimum useful package is a lot-specific certificate of analysis, a mass spectrometry profile that identifies every component present rather than confirming one expected mass, an HPLC trace showing relative abundance, and a net peptide content figure. Third-party verification carries more weight than in-house documentation, and researchers should confirm that the testing was performed on the lot they received rather than on a representative lot.

The third question is whether published results on characterized multi-receptor peptides can be used as a reference point. They cannot, other than as background on the receptor biology. Those publications describe defined molecules with disclosed sequences, measured receptor affinities, and registered study protocols. Applying their findings to a construct of undisclosed composition assumes exactly the equivalence that has never been demonstrated, and that assumption is the single most common error made with research-market metabolic constructs.